

## References

I-211

1. Givlaari (givosiran), injection, for subcutaneous use [package insert]. Alnylam Pharmaceuticals, Inc. Cambridge, MA. 2019. Revised 11/2019.
2. Clinical Pharmacology™ Compendium. 2020. Tampa FL: Gold Standard, Inc. Givosiran.
3. Micromedex DrugDex Compendium®. 2020. Givosiran.
4. Sardh E, Harper P, Balwani M, et al. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. *N Engl J Med.* 2019; 380:549-558.
5. Gouya L, Sardh E, Balwani M, et al. ENVISION, a Phase 3 Study to Evaluate the Efficacy and Safety of Givosiran, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1, in Acute Hepatic Porphyria Patients. *Hepatology.* 2020; 70(1):e81-e82.